First blood-based biomarker in response to the treatment of the most aggressive prostate cancer

(Centro Nacional de Investigaciones Oncológicas (CNIO)) In castration-resistant prostate cancer, the tumors continue to progress even though testosterone production has been blocked; more than 90% of these patients develop metastasis and the survival rate is one to two years.* Using liquid biopsy, a simple blood test has been successful in determining what type of treatment can help to prolong the life expectancy of more than 150 patients